Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
| ▸ | MTOR | P42345 | 1/20 | 0.38 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.38 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.38 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.38 |
| ▸ | PDE3A | Q14432 | 3/20 | 0.36 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.36 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.36 |
| ▸ | CACNA1F | O60840 | 2/20 | 0.35 |
| ▸ | ALB | P02768 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | CACNA1D | Q01668 | 2/20 | 0.35 |
| ▸ | CACNA1S | Q13698 | 2/20 | 0.35 |
| ▸ | CACNA1C | Q13936 | 2/20 | 0.35 |
| ▸ | POLA1 | P09884 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6060293 | 0.85 | PDE3A (0.35) | LMNATHRBMTORMDM2NCOA1 | |
| SCHEMBL29705869 | 0.85 | ABL1 (0.30) | — | |
| SCHEMBL27321202 | 0.81 | PDE3A (0.44) | LMNATHRBMTORMDM2NCOA1 | |
| SCHEMBL29559860 | 0.80 | HCAR3 (0.31) | — | |
| SCHEMBL30286899 | 0.78 | SLC28A1 (0.36) | LMNASLC29A1 | |
| SCHEMBL31189348 | 0.76 | PDE3A (0.48) | LMNATHRBMTORMDM2NCOA1 | |
| SCHEMBL6534202 | 0.76 | PDE3A (0.45) | LMNATHRBMTORMDM2NCOA1 | |
| SCHEMBL31594740 | 0.75 | BLM (0.41) | LMNA | |
| SCHEMBL29414447 | 0.74 | PDE3A (0.42) | LMNATHRBMTORMDM2NCOA1 | |
| SCHEMBL31594723 | 0.74 | PI4KA (0.45) | SLC29A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 106 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240327447-A1 | CHEMICAL SYNTHESIS OF CYTIDINE-5'-MONOPHOSPHO-N-GLYCYL-SIALIC ACID | 89BIO, INC. (US) | 2024-10-03 | — | — | US | claimed |
| CN-118414344-A | Chemical synthesis of cytidine-5' -monophosphate-N-glycyl-sialic acid | 89生物公司 | 2024-07-30 | — | — | CN | claimed |
| EP-4225766-A1 | CHEMICAL SYNTHESIS OF CYTIDINE-5'-MONOPHOSPHO-N-GLYCYL-SIALIC ACID | 89Bio, Inc. (US) | 2023-08-16 | — | — | EP | claimed |
| WO-2023122616-A1 | CHEMICAL SYNTHESIS OF CYTIDINE-5'-MONOPHOSPHO-N-GLYCYL-SIALIC ACID | 89BIO, INC. (US) | 2023-06-29 | — | — | WO | claimed |
| CN-112301118-B | Method and kit for simultaneously obtaining RNA abundance and active RNA polymerase sites in full transcriptome range | 浙江大学 | 2022-05-13 | — | — | CN | claimed |
| US-7776838-B1 | Treatment of chemotherapeutic agent and antiviral agent toxicity with acylated pyrimidine nucleosides | WELLSTAT THERAPEUTICS CORPORATION (US) | 2010-08-17 | — | — | US | claimed |
| EP-1491201-B1 | Methods of reducing toxicity of 5-fluorouracil with acylated pyrimidine nucleosides | WELLSTAT THERAPEUTICS CORP (US) | 2006-03-22 | — | — | EP | claimed |
| EP-0831849-A4 | METHODS OF REDUCING TOXICITY OF CHEMOTHERAPEUTIC AND ANTIVIRAL AGENTS WITH ACYLATED PYRIMIDINE NUCLEOSIDES | WELLSTAT THERAPEUTICS CORP (US) | 2003-03-26 | — | — | EP | claimed |
| US-6344447-B2 | ADMINISTERING MIXTURE OF NUCLEOSIDES; ANTICANCER AGENT | PRO-NEURON, INC. | 2002-02-05 | — | — | US | claimed |
| US-20010025032-A1 | TREATMENT OF CHEMOTHERAPEUTIC AGENT AND ANTIVIRAL AGENT TOXICITY WITH ACYLATED PYRIMIDINE NUCLEOSIDES | VON BORSTEL REID W (US) | 2001-09-27 | — | — | US | claimed |
| EP-0594667-B1 | TREATMENT OF CHEMOTHERAPEUTIC AGENT AND ANTIVIRAL AGENT TOXICITY WITH ACYLATED PYRIMIDINE NUCLEOSIDES | PRO NEURON INC (US) | 2001-09-19 | — | — | EP | claimed |
| US-5968914-A | Treatment of chemotherapeutic agent and antiviral agent toxicity with acylated pyrimidine nucleosides | PRO-NEURON, INC. (US) | 1999-10-19 | — | — | US | claimed |
| EP-0831849-A1 | METHODS OF REDUCING TOXICITY OF CHEMOTHERAPEUTIC AND ANTIVIRAL AGENTS WITH ACYLATED PYRIMIDINE NUCLEOSIDES | PRO-NEURON, INC. (US) | 1998-04-01 | — | — | EP | claimed |
| JP-2584947-B2 | — | — | 1997-02-26 | — | — | JP | claimed |
| WO-1996040165-A1 | METHODS OF REDUCING TOXICITY OF CHEMOTHERAPEUTIC AND ANTIVIRAL AGENTS WITH ACYLATED PYRIMIDINE NUCLEOSIDES | PRO-NEURON, INC. (US) | 1996-12-19 | — | — | WO | claimed |
| EP-0594667-A4 | TREATMENT OF CHEMOTHERAPEUTIC AGENT AND ANTIVIRAL AGENT TOXICITY WITH ACYLATED PYRIMIDINE NUCLEOSIDES | PRO NEURON INC (US) | 1996-01-10 | — | — | EP | claimed |
| WO-1994026761-A1 | TREATMENT OF CHEMOTHERAPEUTIC AGENT AND ANTIVIRAL AGENT TOXICITY WITH ACYLATED PYRIMIDINE NUCLEOSIDES | PRO-NEURON, INC. (US) | 1994-11-24 | — | — | WO | claimed |
| EP-0594667-A1 | TREATMENT OF CHEMOTHERAPEUTIC AGENT AND ANTIVIRAL AGENT TOXICITY WITH ACYLATED PYRIMIDINE NUCLEOSIDES | PRO-NEURON, INC. (US) | 1994-05-04 | — | — | EP | claimed |
| WO-1993001202-A1 | TREATMENT OF CHEMOTHERAPEUTIC AGENT AND ANTIVIRAL AGENT TOXICITY WITH ACYLATED PYRIMIDINE NUCLEOSIDES | PRO-NEURON, INC. (US) | 1993-01-21 | — | — | WO | claimed |
| US-20240327447-A1 | CHEMICAL SYNTHESIS OF CYTIDINE-5'-MONOPHOSPHO-N-GLYCYL-SIALIC ACID | 89BIO, INC. (US) | 2024-10-03 | — | — | US | disclosed |
| CN-118414344-A | Chemical synthesis of cytidine-5' -monophosphate-N-glycyl-sialic acid | 89生物公司 | 2024-07-30 | — | — | CN | disclosed |
| EP-4225766-A1 | CHEMICAL SYNTHESIS OF CYTIDINE-5'-MONOPHOSPHO-N-GLYCYL-SIALIC ACID | 89Bio, Inc. (US) | 2023-08-16 | — | — | EP | disclosed |
| WO-2023122616-A1 | CHEMICAL SYNTHESIS OF CYTIDINE-5'-MONOPHOSPHO-N-GLYCYL-SIALIC ACID | 89BIO, INC. (US) | 2023-06-29 | — | — | WO | disclosed |
| CN-112301118-B | Method and kit for simultaneously obtaining RNA abundance and active RNA polymerase sites in full transcriptome range | 浙江大学 | 2022-05-13 | — | — | CN | disclosed |
| CN-114173780-A | Compounds for reducing the deleterious activity of genes containing extended nucleotide repeats | 小利兰·斯坦福大学托管委员会 | 2022-03-11 | — | — | CN | disclosed |
| US-20220062233-A1 | Compounds for the Reduction of the Deleterious Activity of Extended Nucleotide Repeat Containing Genes | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2022-03-03 | — | — | US | disclosed |
| EP-3897634-A1 | COMPOUNDS FOR THE REDUCTION OF THE DELETERIOUS ACTIVITY OF EXTENDED NUCLEOTIDE REPEAT CONTAINING GENES | The Board of Trustees of the Leland Stanford Junior University (US) | 2021-10-27 | — | — | EP | disclosed |
| US-10882821-B1 | Enantiomeric compound for the reduction of the deleterious activity of extended nucleotide repeat containing genes | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2021-01-05 | — | — | US | disclosed |
| WO-2020131573-A1 | COMPOUNDS FOR THE REDUCTION OF THE DELETERIOUS ACTIVITY OF EXTENDED NUCLEOTIDE REPEAT CONTAINING GENES | NUREDIS, INC. (US) | 2020-06-25 | — | — | WO | disclosed |
| US-10675293-B2 | Nucleoside agents for the reduction of the deleterious activity of extended nucleotide repeat containing genes | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2020-06-09 | — | — | US | disclosed |
| US-20200147069-A1 | Compounds for The Reduction of The Deleterious Activity of Extended Nucleotide Repeat Containing Genes | THE BOARD OF TRUSTEES OF LELAND STANFORD JUNIOR UNIVERSITY | 2020-05-14 | — | — | US | disclosed |
| EP-3641758-A1 | COMPOUNDS FOR THE REDUCTION OF THE DELETERIOUS ACTIVITY OF EXTENDED NUCLEOTIDE REPEAT CONTAINING GENES | The Board of Trustees of the Leland Stanford Junior University (US) | 2020-04-29 | — | — | EP | disclosed |
| CN-110996942-A | Compounds for reducing the deleterious activity of genes containing extended nucleotide repeats | 小利兰.斯坦福大学托管委员会 | 2020-04-10 | — | — | CN | disclosed |
| WO-2018236910-A1 | COMPOUNDS FOR THE REDUCTION OF THE DELETERIOUS ACTIVITY OF EXTENDED NUCLEOTIDE REPEAT CONTAINING GENES | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2018-12-27 | — | — | WO | disclosed |
| EP-3303588-A1 | NUCLEOSIDE AGENTS FOR THE REDUCTION OF THE DELETERIOUS ACTIVITY OF EXTENDED NUCLEOTIDE REPEAT CONTAINING GENES | The Board of Trustees of The Leland Stanford Junior University (US) | 2018-04-11 | — | — | EP | disclosed |
| US-20180064744-A1 | NUCLEOSIDE AGENTS FOR THE REDUCTION OF THE DELETERIOUS ACTIVITY OF EXTENDED NUCLEOTIDE REPEAT CONTAINING GENES | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2018-03-08 | — | — | US | disclosed |
| EP-2295063-B1 | Compositions and the use thereof in the treatment of mitochondrial diseases | WELLSTAT THERAPEUTICS CORP (US) | 2017-04-26 | — | — | EP | disclosed |
| WO-2016196012-A1 | NUCLEOSIDE AGENTS FOR THE REDUCTION OF THE DELETERIOUS ACTIVITY OF EXTENDED NUCLEOTIDE REPEAT CONTAINING GENES | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2016-12-08 | — | — | WO | disclosed |
| EP-1109453-B1 | COMPOSITIONS AND METHODS FOR TREATMENT OF MITOCHONDRIAL DISEASES | WELLSTAT THERAPEUTICS CORP (US) | 2012-07-25 | — | — | EP | disclosed |
| EP-2408306-A1 | SUBSTITUTED NUCLEOSIDE AND NUCLEOTIDE ANALOGS | Alios Biopharma, Inc. (US) | 2012-01-25 | — | — | EP | disclosed |
| US-8067392-B2 | Compositions and methods for treatment of mitochondrial diseases | WELLSTAT THERAPEUTICS CORPORATION (US) | 2011-11-29 | — | — | US | disclosed |
| US-20110144051-A1 | Compositions and methods for treatment of mitochondrial diseases | WELLSTAT THERAPEUTICS CORPORATION (US) | 2011-06-16 | — | — | US | disclosed |
| US-7915233-B1 | Compositions and methods for treatment of mitochondrial diseases | WELLSTAT THERAPEUTICS CORPORATION (US) | 2011-03-29 | — | — | US | disclosed |
| EP-2295063-A2 | Compositions and the use thereof the treatment of mitochondrial diseases | 32 Mott Street Acquisitions I, LLC d/b/a Wellstat Vaccines (US) | 2011-03-16 | — | — | EP | disclosed |
| US-7807654-B2 | Compositions and methods for treatment of mitochondrial diseases | WELLSTAT THERAPEUTICS CORPORATION (US) | 2010-10-05 | — | — | US | disclosed |
| WO-2010108140-A1 | SUBSTITUTED NUCLEOSIDE AND NUCLEOTIDE ANALOGS | ALIOS BIOPHARMA, INC. (US) | 2010-09-23 | — | — | WO | disclosed |
| US-7776838-B1 | Treatment of chemotherapeutic agent and antiviral agent toxicity with acylated pyrimidine nucleosides | WELLSTAT THERAPEUTICS CORPORATION (US) | 2010-08-17 | — | — | US | disclosed |
| US-7709459-B2 | Pyrimidine nucleotide precursors for treatment of systemic inflammation and inflammatory hepatitis | WELLSTAT THERAPEUTICS CORPORATION (US) | 2010-05-04 | — | — | US | disclosed |
| US-7582619-B2 | Compositions and methods for treatment of mitochondrial diseases | WELLSTAT THERAPEUTICS CORPORATION (US) | 2009-09-01 | — | — | US | disclosed |
| EP-1778223-A4 | METHODS AND COMPOSITIONS FOR REDUCING TOXICITY ASSOCIATED WITH LEFLUNOMIDE TREATMENT | WILLIAMS JAMES W (US) | 2008-03-05 | — | — | EP | disclosed |
| EP-1778223-A1 | METHODS AND COMPOSITIONS FOR REDUCING TOXICITY ASSOCIATED WITH LEFLUNOMIDE TREATMENT | Williams, James W. (US) | 2007-05-02 | — | — | EP | disclosed |
| US-7173017-B1 | Antiinflammatory agents and treatment of hepatitis with pyrimidine nucleotides to prevent liver damage | WELLSTAT THERAPEUTICS CORPORATION (US) | 2007-02-06 | — | — | US | disclosed |
| US-7166581-B1 | Treatment of chemotherapeutic agent and antiviral agent toxicity with acylated pyrimidine nucleosides | WELLSTAT THERAPEUTICS CORPORATION (US) | 2007-01-23 | — | — | US | disclosed |
| US-20070010479-A1 | Compositions and methods for treatment of mitochondrial diseases | PRO-NEURON, INC. (US) | 2007-01-11 | — | — | US | disclosed |
| EP-1109453-A4 | COMPOSITIONS AND METHODS FOR TREATMENT OF MITOCHONDRIAL DISEASES | WELLSTAT THERAPEUTICS CORP (US) | 2006-11-02 | — | — | EP | disclosed |
| US-7105498-B2 | Acylated uridine and cytidine and uses thereof | WELLSTAT THERAPEUTICS CORPORATION (US) | 2006-09-12 | — | — | US | disclosed |
| EP-1491201-B1 | Methods of reducing toxicity of 5-fluorouracil with acylated pyrimidine nucleosides | WELLSTAT THERAPEUTICS CORP (US) | 2006-03-22 | — | — | EP | disclosed |
| WO-2006014827-A1 | METHODS AND COMPOSITIONS FOR REDUCING TOXICITY ASSOCIATED WITH LEFLUNOMIDE TREATMENT | UNIV CHICAGO (US) | 2006-02-09 | — | — | WO | disclosed |
| US-20060024376-A1 | Methods and compositions for reducing toxicity associated with leflunomide treatment | THE UNIVERSITY OF CHICAGO (US) | 2006-02-02 | — | — | US | disclosed |
| US-6956028-B2 | Compositions and methods for treatment of mitochondrial diseases | WELLSTAT THERAPEUTICS COPORATION (US) | 2005-10-18 | — | — | US | disclosed |
| US-20050203066-A1 | Compositions and methods for treatment of mitochondrial diseases | WELLSTAT THERAPEUTICS CORPORATION (US) | 2005-09-15 | — | — | US | disclosed |
| EP-1486210-A1 | Pyrimidine nucleotide precursors for treatment of inflammatory hepatitis | Wellstat Therapeutics Corporation (US) | 2004-12-15 | — | — | EP | disclosed |
| EP-0679160-B1 | PYRIMIDINE NUCLEOTIDE PRECURSORS FOR TREATMENT OF INFLAMMATORY HEPATITIS | WELLSTAT THERAPEUTICS CORP (US) | 2004-11-17 | — | — | EP | disclosed |
| US-20040220134-A1 | Pyrimidine nucleotide precursors for treatment of systemic inflammation and inflammatory hepatitis | PRO-NEURON, INC. (US) | 2004-11-04 | — | — | US | disclosed |
| EP-1416795-A4 | COMPOSITIONS AND METHODS FOR TREATMENT OF MITOCHONDRIAL DISEASES | WELLSTAT THERAPEUTICS CORP (US) | 2004-09-15 | — | — | EP | disclosed |
| EP-0768883-A4 | PYRIMIDINE NUCLEOTIDE PRECURSORS FOR TREATMENT OF SYSTEMIC INFLAMMATION AND INFLAMMATORY HEPATITIS | WELLSTAT THERAPEUTICS CORP (US) | 2004-09-15 | — | — | EP | disclosed |
| EP-1416795-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF MITOCHONDRIAL DISEASES | Wellstat Therapeutics Corporation (US) | 2004-05-12 | — | — | EP | disclosed |
| US-20040033981-A1 | Pyrimidine nucleotide precursors for treatment of systemic inflammation and inflammatory hepatitis | PRO-NEURON INC. | 2004-02-19 | — | — | US | disclosed |
| US-20030212036-A1 | Pyrimidine nucleotide precursors for treatment of systemic inflammation and inflammatory heptitis | PRO NEURON, INC. | 2003-11-13 | — | — | US | disclosed |
| EP-0831849-A4 | METHODS OF REDUCING TOXICITY OF CHEMOTHERAPEUTIC AND ANTIVIRAL AGENTS WITH ACYLATED PYRIMIDINE NUCLEOSIDES | WELLSTAT THERAPEUTICS CORP (US) | 2003-03-26 | — | — | EP | disclosed |
| WO-2003015516-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF MITOCHONDRIAL DISEASES | WELLSTAT THERAPEUTICS CORPORATION (US) | 2003-02-27 | — | — | WO | disclosed |
| US-6472378-B2 | PREVENTING OR TREATING PATHOPHYSIOLOGICAL CONSEQUENCES OF MITOCHONDRIAL RESPIRATORY CHAIN DYSFUNCTION IN A MAMMAL BY ADMINISTERING A PYRIMIDINE NUCLEOTIDE PRECURSOR; TREATING CHEMOTHERAPY SIDE EFFECTS, FOR EXAMPLE | PRO-NEURON, INC. | 2002-10-29 | — | — | US | disclosed |
| US-20020049182-A1 | Administering to a mammal a composition containing pyrimidine nucleotide precursors in amounts sufficient to treat symptoms resulting from mitochondrial respiratory chain deficiencies. | WELLSTAT THERAPEUTICS CORPORATION | 2002-04-25 | — | — | US | disclosed |
| US-20020035086-A1 | Acylated uridine and cytidine and uses thereof | PRO NEURON, INC. | 2002-03-21 | — | — | US | disclosed |
| US-6344447-B2 | ADMINISTERING MIXTURE OF NUCLEOSIDES; ANTICANCER AGENT | PRO-NEURON, INC. | 2002-02-05 | — | — | US | disclosed |
| US-6329350-B1 | ADMINISTERING CYTOKINES AS ANTICARCINOGENIC AND ANTIINFLAMMATORY AGENTS | PRO-NEURON, INC. | 2001-12-11 | — | — | US | disclosed |
| US-6316426-B1 | NUCLEOSIDE DERIVATIVE FOR DIABETES, HEART DISEASE, CEREBROVASCULAR DISORDERS, PARKINSON'S DISEASE, INFANT RESPIRATORY DISTRESS SYNDROME AND FOR ENHANCEMENT OF PHOSPHOLIPID BIOSYNTHESIS | PRO-NEURON, INC. | 2001-11-13 | — | — | US | disclosed |
| US-20010025032-A1 | TREATMENT OF CHEMOTHERAPEUTIC AGENT AND ANTIVIRAL AGENT TOXICITY WITH ACYLATED PYRIMIDINE NUCLEOSIDES | VON BORSTEL REID W (US) | 2001-09-27 | — | — | US | disclosed |
| EP-0594667-B1 | TREATMENT OF CHEMOTHERAPEUTIC AGENT AND ANTIVIRAL AGENT TOXICITY WITH ACYLATED PYRIMIDINE NUCLEOSIDES | PRO NEURON INC (US) | 2001-09-19 | — | — | EP | disclosed |
| US-20010016576-A1 | Compositions and methods for treatment of mitochondrial diseases | PRO-NEURON, INC. | 2001-08-23 | — | — | US | disclosed |
| US-6274563-B1 | ADMINISTERING AS ANTIDIABETIC AGENT | PRO-NEURON, INC. | 2001-08-14 | — | — | US | disclosed |
| US-6258795-B1 | Acylated uridine and cytidine and uses thereof | PRO-NEURON, INC. | 2001-07-10 | — | — | US | disclosed |
| US-20010005719-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF MITOCHONDRIAL DISEASES | WELLSTAT THERAPEUTICS CORPORATION | 2001-06-28 | — | — | US | disclosed |
| EP-1109453-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF MITOCHONDRIAL DISEASES | Wellstat Therapeutics Corporation (US) | 2001-06-27 | — | — | EP | disclosed |
| US-6232298-B1 | ADMINISTERING URIDINE, CYTIDINE, OR OROTIC ACID OR SALT OR ACYLATED DERIVATIVE TO TREAT CACHEXIA | PRO-NEURON, INC. | 2001-05-15 | — | — | US | disclosed |
| WO-2000011952-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF MITOCHONDRIAL DISEASES | PRO-NEURON, INC. (US) | 2000-03-09 | — | — | WO | disclosed |
| US-5968914-A | Treatment of chemotherapeutic agent and antiviral agent toxicity with acylated pyrimidine nucleosides | PRO-NEURON, INC. (US) | 1999-10-19 | — | — | US | disclosed |
| US-5736531-A | ADMINISTERING TO TREAT AND PREVENT TOXICITY | PRO-NEURON, INC. (US) | 1998-04-07 | — | — | US | disclosed |
| EP-0831849-A1 | METHODS OF REDUCING TOXICITY OF CHEMOTHERAPEUTIC AND ANTIVIRAL AGENTS WITH ACYLATED PYRIMIDINE NUCLEOSIDES | PRO-NEURON, INC. (US) | 1998-04-01 | — | — | EP | disclosed |
| US-5691320-A | RESISTANCE TO SEPSIS, INFLAMMATION | PRO-NEURON, INC. (US) | 1997-11-25 | — | — | US | disclosed |
| EP-0679160-A4 | PYRIMIDINE NUCLEOTIDE PRECURSORS FOR TREATMENT OF SYSTEMIC INFLAMMATION AND INFLAMMATORY HEPATITIS. | PRO NEURON INC (US) | 1997-06-11 | — | — | EP | disclosed |
| EP-0768883-A1 | PYRIMIDINE NUCLEOTIDE PRECURSORS FOR TREATMENT OF SYSTEMIC INFLAMMATION AND INFLAMMATORY HEPATITIS | PRO-NEURON, INC. (US) | 1997-04-23 | — | — | EP | disclosed |
| WO-1996040165-A1 | METHODS OF REDUCING TOXICITY OF CHEMOTHERAPEUTIC AND ANTIVIRAL AGENTS WITH ACYLATED PYRIMIDINE NUCLEOSIDES | PRO-NEURON, INC. (US) | 1996-12-19 | — | — | WO | disclosed |
| US-5583117-A | CARDIOVASCULAR, NERVOUS SYSTEM DISORDERS; DIABETES | PRO-NEURON, INC. (US) | 1996-12-10 | — | — | US | disclosed |
| WO-1996001115-A1 | PYRIMIDINE NUCLEOTIDE PRECURSORS FOR TREATMENT OF SYSTEMIC INFLAMMATION AND INFLAMMATORY HEPATITIS | PRO-NEURON, INC. (US) | 1996-01-18 | — | — | WO | disclosed |
| EP-0594667-A4 | TREATMENT OF CHEMOTHERAPEUTIC AGENT AND ANTIVIRAL AGENT TOXICITY WITH ACYLATED PYRIMIDINE NUCLEOSIDES | PRO NEURON INC (US) | 1996-01-10 | — | — | EP | disclosed |
| US-5470838-A | Method of delivering exogenous uridine or cytidine using acylated uridine or cytidine | PRO-NEURON, INC. (US) | 1995-11-28 | — | — | US | disclosed |
| EP-0679160-A1 | PYRIMIDINE NUCLEOTIDE PRECURSORS FOR TREATMENT OF SYSTEMIC INFLAMMATION AND INFLAMMATORY HEPATITIS | PRO-NEURON, INC. (US) | 1995-11-02 | — | — | EP | disclosed |
| WO-1994026761-A1 | TREATMENT OF CHEMOTHERAPEUTIC AGENT AND ANTIVIRAL AGENT TOXICITY WITH ACYLATED PYRIMIDINE NUCLEOSIDES | PRO-NEURON, INC. (US) | 1994-11-24 | — | — | WO | disclosed |
| WO-1994013687-A1 | PYRIMIDINE NUCLEOTIDE PRECURSORS FOR TREATMENT OF SYSTEMIC INFLAMMATION AND INFLAMMATORY HEPATITIS | PRO-NEURON, INC. (US) | 1994-06-23 | — | — | WO | disclosed |
| EP-0594667-A1 | TREATMENT OF CHEMOTHERAPEUTIC AGENT AND ANTIVIRAL AGENT TOXICITY WITH ACYLATED PYRIMIDINE NUCLEOSIDES | PRO-NEURON, INC. (US) | 1994-05-04 | — | — | EP | disclosed |
| EP-0339075-B1 | ACYLATED URIDINE AND CYTIDINE AND USES THEREOF | PRO-NEURON, INC. (US) | 1993-08-18 | — | — | EP | disclosed |
| WO-1993001202-A1 | TREATMENT OF CHEMOTHERAPEUTIC AGENT AND ANTIVIRAL AGENT TOXICITY WITH ACYLATED PYRIMIDINE NUCLEOSIDES | PRO-NEURON, INC. (US) | 1993-01-21 | — | — | WO | disclosed |
| EP-0339075-A4 | ACYLATED URIDINE AND CYTIDINE AND USES THEREOF. | PRO NEURON INC (US) | 1990-04-10 | — | — | EP | disclosed |
| EP-0339075-A1 | ACYLATED URIDINE AND CYTIDINE AND USES THEREOF | PRO-NEURON, INC. (US) | 1989-11-02 | — | — | EP | disclosed |
| WO-1989003837-A1 | ACYLATED URIDINE AND CYTIDINE AND USES THEREOF | PRO-NEURON, INC. (US) | 1989-05-05 | — | — | WO | disclosed |
| WO-1989003837-A1 | ACYLATED URIDINE AND CYTIDINE AND USES THEREOF | PRO-NEURON, INC. (US) | 1989-05-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (18 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020049182-A1 | Administering to a mammal a composition containing pyrimidine nucleotide precursors in amounts sufficient to treat symptoms resulting from mitochondrial respiratory chain deficiencies. | POLRMT, TK2, NUDT1 | LMNA 930/4885THRB 2471/4885MTOR 3206/4885 |
| US-20040033981-A1 | Pyrimidine nucleotide precursors for treatment of systemic inflammation and inflammatory hepatitis | UMPS, PNP, TYMP | LMNA 4224/4885THRB 2680/4885MTOR 1168/4885 |
| US-20180064744-A1 | NUCLEOSIDE AGENTS FOR THE REDUCTION OF THE DELETERIOUS ACTIVITY OF EXTENDED NUCLEOTIDE REPEAT CONTAINING GENES | NSUN2, RNGTT, ADAR | LMNA 825/4885THRB 2629/4885MTOR 4467/4885 |
| US-20110144051-A1 | Compositions and methods for treatment of mitochondrial diseases | POLRMT, TK2, UQCRC2 | LMNA 655/4885THRB 3511/4885MTOR 2006/4885 |
| US-20030212036-A1 | Pyrimidine nucleotide precursors for treatment of systemic inflammation and inflammatory heptitis | UMPS, TYMP, PNP | LMNA 4566/4885THRB 3415/4885MTOR 1052/4885 |
| US-20220062233-A1 | Compounds for the Reduction of the Deleterious Activity of Extended Nucleotide Repeat Containing Genes | NSUN2, RTCB, RRM2B | LMNA 1237/4885THRB 1337/4885MTOR 3756/4885 |
| US-10882821-B1 | Enantiomeric compound for the reduction of the deleterious activity of extended nucleotide repeat containing genes | NSUN2, RRM2B, RNMT | LMNA 512/4885THRB 545/4885MTOR 4136/4885 |
| US-20020035086-A1 | Acylated uridine and cytidine and uses thereof | UMPS, PDF, RNASE1 | LMNA 2288/4885THRB 3764/4885MTOR 4142/4885 |
| US-20240327447-A1 | CHEMICAL SYNTHESIS OF CYTIDINE-5'-MONOPHOSPHO-N-GLYCYL-SIALIC ACID | NEU2, NEU1, FUT5 | LMNA 2064/4885THRB 4667/4885MTOR 3314/4885 |
| US-20050203066-A1 | Compositions and methods for treatment of mitochondrial diseases | POLRMT, TK2, UQCRC1 | LMNA 557/4885THRB 3126/4885MTOR 2219/4885 |
| US-20010005719-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF MITOCHONDRIAL DISEASES | POLRMT, TK2, UQCRC1 | LMNA 557/4885THRB 3126/4885MTOR 2219/4885 |
| US-20200147069-A1 | Compounds for The Reduction of The Deleterious Activity of Extended Nucleotide Repeat Containing Genes | NSUN2, RNMT, RRM2B | LMNA 456/4885THRB 818/4885MTOR 4124/4885 |
| US-10675293-B2 | Nucleoside agents for the reduction of the deleterious activity of extended nucleotide repeat containing genes | NSUN2, RNGTT, ADAR | LMNA 825/4885THRB 2629/4885MTOR 4467/4885 |
| US-20010025032-A1 | TREATMENT OF CHEMOTHERAPEUTIC AGENT AND ANTIVIRAL AGENT TOXICITY WITH ACYLATED PYRIMIDINE NUCLEOSIDES | TYMP, NUDT1, UNG | LMNA 3231/4885THRB 4597/4885MTOR 1968/4885 |
| US-20040220134-A1 | Pyrimidine nucleotide precursors for treatment of systemic inflammation and inflammatory hepatitis | UMPS, PNP, TYMP | LMNA 4224/4885THRB 2680/4885MTOR 1168/4885 |
| US-20060024376-A1 | Methods and compositions for reducing toxicity associated with leflunomide treatment | TPMT, TYMP, LEF1 | LMNA 1208/4885THRB 4695/4885MTOR 2535/4885 |
| US-20070010479-A1 | Compositions and methods for treatment of mitochondrial diseases | POLRMT, TK2, UQCRC1 | LMNA 557/4885THRB 3126/4885MTOR 2219/4885 |
| US-20010016576-A1 | Compositions and methods for treatment of mitochondrial diseases | POLRMT, TK2, UQCRC1 | LMNA 557/4885THRB 3126/4885MTOR 2219/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.